SCHEDULE: Janus Henderson Discloses Collegium Pharma Stake

Janus Henderson Group plc has reported beneficial ownership of 5.8% of Collegium Pharmaceutical, Inc. common stock as of March 31, 2026.

Summary

• Janus Henderson Group plc, through its various asset management subsidiaries, has disclosed beneficial ownership of 1,825,651 shares of Collegium Pharmaceutical, Inc. common stock.
• This holding represents 5.8% of the total class of securities.
• The filing indicates that the asset managers exercise investment and/or voting discretion on behalf of their clients, which include investment companies, other investment advisers, and various separate accounts.
• However, these asset managers do not have the right to receive dividends or the proceeds from the sale of these securities and disclaim any ownership associated with these rights.
• The filing is made under Schedule 13G, indicating it is an informational filing by an institutional investor.
• The reporting date for this event is March 31, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of institutional ownership and does not contain performance data or strategic announcements.

Positives

• Janus Henderson Group plc, a significant institutional investor, holds a notable stake in Collegium Pharmaceutical, Inc., suggesting confidence in the company's prospects.
• The 5.8% ownership indicates a substantial investment, which can provide stability and support for the company's stock.

Negatives

• The filing explicitly states that the asset managers do not have the right to receive dividends or proceeds from the sale of the securities, limiting their direct financial benefit from the holdings.
• The beneficial ownership is shared across multiple asset managers, potentially diluting direct control or influence by any single entity within Janus Henderson Group.

Risks

• The filing does not explicitly mention any risks related to Collegium Pharmaceutical, Inc. itself, as it is a disclosure of ownership by an institutional investor.
• Potential risks for Janus Henderson Group plc could include market volatility affecting the value of their investment in Collegium Pharmaceutical, Inc.

Future Outlook

This filing is a disclosure of current ownership and does not contain forward-looking statements or guidance from Collegium Pharmaceutical, Inc. or Janus Henderson Group plc regarding future performance.

Management Comments

• "The Asset Managers generally exercise investment and/or voting discretion on behalf of their clients which include investment companies, other investment advisers, institutional separate accounts and retail separate accounts (collectively referred to herein as Managed Portfolios)."
• "However, the Asset Managers do not have the right to receive any dividends from, or the proceeds from the sale of, the securities held in the Managed Portfolios and disclaim any ownership associated with such rights."
• "Please note that not every Asset Manager has investment and/or voting discretion over the securities reported herein."

Industry Context

StockSavvy.ai notes that this Schedule 13G filing by Janus Henderson Group plc indicates a significant institutional holding in Collegium Pharmaceutical, Inc. Such filings are common for large asset managers and reflect their investment strategies and portfolio allocations within the pharmaceutical sector.

Stakeholder Impact

• Shareholders of Collegium Pharmaceutical, Inc.: The significant holding by a major institutional investor like Janus Henderson Group plc can be viewed positively, potentially indicating stability and institutional support for the stock.
• Janus Henderson Group plc clients: The investment is managed on behalf of clients, and the performance of Collegium Pharmaceutical, Inc. will impact their portfolio returns.

Next Steps

• Janus Henderson Group plc will continue to manage its investment in Collegium Pharmaceutical, Inc. according to its investment strategies.
• Collegium Pharmaceutical, Inc. will continue its business operations as disclosed in its other SEC filings.

Key Dates

Keywords

Collegium Pharmaceutical, Janus Henderson Group, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Investment Management